Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B

Lung Cancer

Volumn 31, Issue 2-3, 2001, Pages 311-317

  Kindler, Hedy L ^a   Millard, Frederick ^b   Herndon II, James E ^c   Vogelzang, Nicholas J ^a   Suzuki, Yasunosuke ^d   Green, Mark R ^e  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c CALGB Statistical Center   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chemotherapy; Gemcitabine; Mesothelioma

Indexed keywords

GEMCITABINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DRUG INFUSION; DRUG RESPONSE; EPITHELIUM CELL; FEMALE; HUMAN; INFECTION; LYMPHOCYTOPENIA; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESOTHELIOMA; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0035141576     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00166-5     Document Type: Article

References (27)

1. Chemotherapy in malignant pleural mesothelioma: a review
2. Mesothelioma
3. A review of chemotherapy trials in malignant mesothelioma
4. Malignant pleural mesothelioma
5. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study
6. High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma
7. Edatrexate for Malignant Mesothelioma: a phase II study of the Cancer and Leukemia Group B, 9131
8. Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B phase II study
9. Dihydro-5-azacytidine in malignant mesothelioma: a phase II trial demonstrating activity accompanied by cardiac toxicity
10. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B
11. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine
12. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study
13. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
14. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
15. The role of gemcitabine in the treatment of other tumors
16. One-sample multiple testing procedure for phase II clinical trials
17. Planned versus attained design in phase II clinical trials
18. Nonparametric estimation from incomplete observations
19. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
20. A phase II study of gemcitabine in patients with malignant pleural mesothelioma
21. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma
22. Cisplatin and gemcitabine for malignant mesothelioma: a phase II study
23. Robinson BWS. Gemcitabine activity on murine and human malignant mesothelioma cell lines show additive activity in combination with cisplatin
24. Synergistic interaction between cisplatin and gemcitabine in vitro
25. Weekly gemcitabine with monthly cisplatin: Effective therapy for advanced non-small cell lung cancer
26. Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV
27. Individual variation in response to cytostatic chemotherapy in the treatment of mesothelioma: In vitro studies in human cell lines